Immunome Inc (IMNM)

$19.37 +2.28 (13.34%)
Market Cap 1.57B
Revenue (ttm) 9.04M
Net Income (ttm) -292.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,240.71%
Debt to Equity Ratio 0.00
Volume 2,112,900
Avg Vol 1,491,556
Day's Range N/A - N/A
Shares Out 91.71M
Stochastic %K 90%
Beta 2.17
Analysts Strong Sell
Price Target $25.67

Company Profile

Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug...

Industry: Biotechnology
Sector: Healthcare
Phone: 425 939 7410
Address:
18702 North Creek Parkway, Suite 100, Bothell, United States
Fast_Eddie_Felson
Fast_Eddie_Felson Dec. 4 at 5:23 PM
$IMNM just pump to 50, thanks
0 · Reply
Iightning
Iightning Dec. 4 at 6:22 AM
1ightning® Premium Options Alert (Actionable) Ticker: $IMNM Contract: Dec 19 $20C Entry: 3.90 Exit: 5.01 Return: +28.41% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
HunterT
HunterT Dec. 3 at 6:55 PM
$IMNM go baby go! $36 with good news on the way!
1 · Reply
Godwins26
Godwins26 Dec. 3 at 6:29 PM
3rd Watchlist today 😊 $PLRZ $ARWR $MAZE $BEAM $IMNM
0 · Reply
Whitesheep
Whitesheep Dec. 3 at 3:44 PM
$IMNM Sold @19, having bought @17,40 - could luck to those who hang on 😁
0 · Reply
Iightning
Iightning Dec. 2 at 12:39 AM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $IMNM **Contract:** Dec 19 $19C **Entry:** 4.35 **Exit:** 5.42 **Return:** **+24.56% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
JarvisFlow
JarvisFlow Dec. 1 at 2:22 PM
Truist Securities updates rating for Immunome ( $IMNM ) to Buy, target set at 36.
0 · Reply
Iightning
Iightning Nov. 26 at 3:32 AM
1ightning® Options Trade Alert (Actionable) | Buy $IMNM Dec 19 $19 Call | Enter: $4.59 Exit: $7.87 | Profit: 71.43% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 1:37 PM
1ightning® Options Trade Alert (Actionable) | Buy $IMNM Dec 19 $19 Call | Enter: $4.59 Exit: $7.87 | Profit: 71.43% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 2:31 AM
1ightning® Options Trade Alert (Actionable) | Buy $IMNM Dec 19 $19 Call | Enter: $4.59 Exit: $7.87 | Profit: 71.43% ROI | https://1ightning.com
0 · Reply
Latest News on IMNM
Immunome to Present at Upcoming Investor Conferences

Nov 25, 2025, 8:00 AM EST - 9 days ago

Immunome to Present at Upcoming Investor Conferences

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 6, 2025, 4:05 PM EST - 27 days ago

Immunome Reports Third Quarter 2025 Financial Results and Provides Business Update

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nov 4, 2025, 4:05 PM EST - 4 weeks ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference

Oct 31, 2025, 11:51 AM EDT - 4 weeks ago

Immunome to Present at 2nd Annual Guggenheim Healthcare Innovation Conference

Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance

Oct 23, 2025, 12:00 PM EDT - 6 weeks ago

Immunome Presents Preclinical Data Showing Proprietary TOP1i ADC Payload HC74 Overcomes Multiple Mechanisms of ADC Resistance

Infinimmune Announces Research Collaboration with Immunome

Sep 18, 2025, 8:00 AM EDT - 2 months ago

Infinimmune Announces Research Collaboration with Immunome

Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 3 months ago

Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Immunome: SpringWorks Buyout Informs The Potential Upside Here

Aug 11, 2025, 10:31 PM EDT - 4 months ago

Immunome: SpringWorks Buyout Informs The Potential Upside Here

Immunome (IMNM) Q2 Revenue Surges 382%

Aug 6, 2025, 5:32 PM EDT - 4 months ago

Immunome (IMNM) Q2 Revenue Surges 382%

Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 4:05 PM EDT - 4 months ago

Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:05 PM EDT - 7 months ago

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

Immunome: Transformed Pipeline Offers Multiple Catalysts

Apr 17, 2025, 6:06 AM EDT - 8 months ago

Immunome: Transformed Pipeline Offers Multiple Catalysts

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 4, 2025, 8:00 AM EDT - 8 months ago

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

Immunome Reports Full Year 2024 Financial Results and Provides Business Update

Mar 19, 2025, 4:05 PM EDT - 9 months ago

Immunome Reports Full Year 2024 Financial Results and Provides Business Update

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

Mar 10, 2025, 7:41 AM EDT - 9 months ago

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

Immunome to Present at Upcoming March Conferences

Feb 25, 2025, 8:00 AM EST - 10 months ago

Immunome to Present at Upcoming March Conferences

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 31, 2025, 4:01 PM EST - 10 months ago

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Immunome Can Take The Fight To Competitors With Varegacestat

Jan 30, 2025, 10:27 AM EST - 11 months ago

Immunome Can Take The Fight To Competitors With Varegacestat

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Jan 29, 2025, 11:11 PM EST - 11 months ago

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Immunome Announces Proposed Public Offering of Common Stock

Jan 29, 2025, 4:27 PM EST - 11 months ago

Immunome Announces Proposed Public Offering of Common Stock

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 8:00 AM EST - 11 months ago

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 1 year ago

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 13, 2024, 4:05 PM EST - 1 year ago

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Nov 5, 2024, 8:00 AM EST - 1 year ago

Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Oct 8, 2024, 8:05 AM EDT - 1 year ago

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Immunome: AL102 And Other Established Protein Targets Could Drive Value

Jun 27, 2024, 2:14 PM EDT - 1 year ago

Immunome: AL102 And Other Established Protein Targets Could Drive Value

Immunome Appoints Phil Tsai as Chief Technical Officer

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Immunome Appoints Phil Tsai as Chief Technical Officer

Immunome Announces Completion of Purchase of Assets from Atreca

May 20, 2024, 8:00 AM EDT - 1 year ago

Immunome Announces Completion of Purchase of Assets from Atreca

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

May 17, 2024, 8:00 AM EDT - 1 year ago

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

May 14, 2024, 8:00 AM EDT - 1 year ago

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

Immunome to Present at 2024 Bank of America Healthcare Conference

May 8, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present at 2024 Bank of America Healthcare Conference

Immunome Appoints Kinney Horn as Chief Business Officer

May 2, 2024, 8:00 AM EDT - 1 year ago

Immunome Appoints Kinney Horn as Chief Business Officer

Immunome Appoints Sandra M. Swain to Board of Directors

Apr 25, 2024, 8:26 AM EDT - 1 year ago

Immunome Appoints Sandra M. Swain to Board of Directors

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Apr 5, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Immunome: An Oncology Powerhouse In The Making

Apr 2, 2024, 2:07 PM EDT - 1 year ago

Immunome: An Oncology Powerhouse In The Making

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Mar 28, 2024, 4:02 PM EDT - 1 year ago

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies

Mar 18, 2024, 5:44 AM EDT - 1 year ago

Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies

Immunome to Participate in the Leerink Partners Global Biopharma Conference

Mar 7, 2024, 8:00 AM EST - 1 year ago

Immunome to Participate in the Leerink Partners Global Biopharma Conference

Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference

Mar 1, 2024, 8:00 AM EST - 1 year ago

Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference

Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

Feb 20, 2024, 8:15 AM EST - 1 year ago

Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

Immunome Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 16, 2024, 4:05 PM EST - 1 year ago

Immunome Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Immunome Announces Pricing of Public Offering of Common Stock

Feb 13, 2024, 10:38 PM EST - 1 year ago

Immunome Announces Pricing of Public Offering of Common Stock

Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

Feb 6, 2024, 8:00 AM EST - 1 year ago

Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

Fast_Eddie_Felson
Fast_Eddie_Felson Dec. 4 at 5:23 PM
$IMNM just pump to 50, thanks
0 · Reply
Iightning
Iightning Dec. 4 at 6:22 AM
1ightning® Premium Options Alert (Actionable) Ticker: $IMNM Contract: Dec 19 $20C Entry: 3.90 Exit: 5.01 Return: +28.41% ROI Unlock VIP Access → https://1ightning.com
0 · Reply
HunterT
HunterT Dec. 3 at 6:55 PM
$IMNM go baby go! $36 with good news on the way!
1 · Reply
Godwins26
Godwins26 Dec. 3 at 6:29 PM
3rd Watchlist today 😊 $PLRZ $ARWR $MAZE $BEAM $IMNM
0 · Reply
Whitesheep
Whitesheep Dec. 3 at 3:44 PM
$IMNM Sold @19, having bought @17,40 - could luck to those who hang on 😁
0 · Reply
Iightning
Iightning Dec. 2 at 12:39 AM
**1ightning® Premium Options Alert (Actionable)** **Ticker:** $IMNM **Contract:** Dec 19 $19C **Entry:** 4.35 **Exit:** 5.42 **Return:** **+24.56% ROI** This is the level of accuracy our VIP desk delivers daily. If you want **institutional-grade scalps without the noise**, join us. **Unlock VIP Access → https://1ightning.com**
0 · Reply
JarvisFlow
JarvisFlow Dec. 1 at 2:22 PM
Truist Securities updates rating for Immunome ( $IMNM ) to Buy, target set at 36.
0 · Reply
Iightning
Iightning Nov. 26 at 3:32 AM
1ightning® Options Trade Alert (Actionable) | Buy $IMNM Dec 19 $19 Call | Enter: $4.59 Exit: $7.87 | Profit: 71.43% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 1:37 PM
1ightning® Options Trade Alert (Actionable) | Buy $IMNM Dec 19 $19 Call | Enter: $4.59 Exit: $7.87 | Profit: 71.43% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 25 at 2:31 AM
1ightning® Options Trade Alert (Actionable) | Buy $IMNM Dec 19 $19 Call | Enter: $4.59 Exit: $7.87 | Profit: 71.43% ROI | https://1ightning.com
0 · Reply
aletz
aletz Nov. 24 at 9:50 PM
$IMNM https://www.biostockinfo.com/biotech-catalyst-ai-scanner-november-wk4/ Came #1 on this week's AI scanner, pivotal data imminent
0 · Reply
KirRoyalTrader
KirRoyalTrader Nov. 23 at 9:49 PM
$IMNM
0 · Reply
Iightning
Iightning Nov. 21 at 11:46 PM
1ightning® Options Trade Alert (Actionable) | Buy $IMNM Dec 19 $18 Call | Enter: $5.21 Exit: $9.41 | Profit: 80.53% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 21 at 3:06 AM
1ightning® Options Trade Alert (Actionable) | Buy $IMNM Dec 19 $18 Call | Enter: $5.21 Exit: $9.41 | Profit: 80.53% ROI | https://1ightning.com
0 · Reply
macroaxis
macroaxis Nov. 21 at 1:37 AM
$IMNM – Volatility Surge: Rising Pin Risk in Immunome Options – Stay Alert for Trading Opportunities https://www.macroaxis.com/stock-options/IMNM/Immunome?utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
Iightning
Iightning Nov. 20 at 12:30 AM
1ightning® Options Trade Alert (Actionable) | Buy $IMNM Dec 19 $18 Call | Enter: $5.21 Exit: $9.41 | Profit: 80.53% ROI | https://1ightning.com
0 · Reply
Iightning
Iightning Nov. 19 at 8:44 AM
1ightning® Options Trade Alert (Actionable) | Buy $IMNM Dec 19 $18 Call | Enter: $5.21 Exit: $9.41 | Profit: 80.53% ROI | https://1ightning.com
0 · Reply
JarvisFlow
JarvisFlow Nov. 17 at 1:00 PM
Stephens & Co. updates rating for Immunome ( $IMNM ) to Overweight, target set at 25 → 33.
0 · Reply
outlawinvestor1
outlawinvestor1 Nov. 14 at 6:15 PM
$IMNM vare ph3 readout coming...🤞
0 · Reply
InvestorWisdom
InvestorWisdom Nov. 14 at 4:28 PM
$IMNM This one could be ready to push out of a 4 week base and start a new uptrend
0 · Reply
RadioIsotope25
RadioIsotope25 Nov. 12 at 11:19 PM
Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204 $IMNM $RADX $MNPR https://finance.yahoo.com/news/radiopharm-theranostics-starts-enrollment-third-133000810.html
0 · Reply
HunterT
HunterT Nov. 11 at 8:48 PM
$IMNM nice march upwards into data!
0 · Reply